NATIONAL DIABETES 
ADVISORY BOARD 
Mailing Address: P.O. Box 30174 
Office: 7550 Wisconsin Avenue, Room616 
Telephone: (30 i ) 496-6045 
BETHESOA, MARYLAND 20014 
October 23, 1978 
Dr. Donald S. Fredrickson 
Director, National Institutes of Health 
Building #1, Room 124 
Bethesda, Maryland 20014 
Dear Dr. Fredricksons 
The Insulin Study Committee of ihe National Diabetes Advisory 
Board submitted its Report to Congress in June of 1978. 
Needless to say, we are grateful for your participation in 
the analysis of the problem and your part in the development 
of the Report. The Recommendations within the Report to 
the various government agencies were formulated after a detailed 
survey of the available data, testimony taken from expert 
witnesses, and much discussion and analyzing of the accumulated 
information by committee members, staff, consultants and 
members of the National Diabetes Advisory Board. 
The Recommendations to the National Institutes of Health 
contained within the Report on pages three and four is 
as follows! 
To obtain the information needed for its report, 
the National Diabetes Data Group should be responsible 
for assembling the data in collaboration with the 
Food and Drug Administration, the Federal Preparedness 
Agency, the Department of Agriculture, the National 
Center for Health Statistics, the Department of Commerce, 
the National Institutes of Health, the Center for 
Disease Control, and the private sector. 
Recombinant DNA Technology 
The Insulin Study Committee has determined that the 
successful application of recombinant DNA technology 
could result in a virtually limitless supply of insulin. 
Therefore, the Committee recommends that research on 
the development of synthetic insulin production by means 
of this technology should continue and should be encouraged 
by the Federal and private biomedical research community. 
[A-435] 
